Early Trading Has Evaxion A/S (EVAX) on the Move for June 23

Equities Staff  |

Evaxion Biotech A/S - ADR (NASDAQ:EVAX) is active in pre-market trading today, June 23, with shares falling 6.25% from the last closing price.

The stock is down 60.18% year-to-date while moving 4.76% higher over the last 5 days.

For technical charts, analysis, and more on Evaxion A/S visit the company profile.

Pre-market prices and movements as of 06:22:26 est.

About Evaxion Biotech A/S - ADR

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

To get more information on Evaxion Biotech A/S - ADR and to follow the company's latest updates, you can visit the company's profile page here: Evaxion Biotech A/S - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content